Aucentra Therapeutics

OUR MISSION: To develop targeted cancer therapeutics that provide better outcomes for patients.

We’re building an Australian company with an ambitious vision to revolutionise cancer treatment across the globe. With exceptional expertise in drug discovery and pre-clinical development, a pipeline of promising drug candidates, and a team comprised of experienced executives, Aucentra is poised for success.

All of our compounds are designed to be first-in-class or best-in-class anticancer agents. Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.

Investment opportunity

Equity finance

Gallery images

Investor information


No documents provided.

Project status update

Aucentra recently initiated its Phase 1a/b study of Auceliciclib (AU3-14) in Glioblastoma Multiforme (GBM) patients in combination with Temozolomide.

Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.

If you are interested in transforming cancer treatments across the globe, contact us today to discuss opportunities to invest in Aucentra.

Project dependencies


Technology utilised

AU-07 Oral CDK9 inhibitor: Phase I - Acute myeloid leukemia, hematological malignancies
AU3-14 Oral CDK4/6 inhibitor: Phase 1a/b – solid tumors, ovarian, colorectal, GBM
AU2-94 Oral CDK4 inhibitor: Late Pre-Clinical, colorectal cancer, GBM, ovarian cancer, hematological cancer
AU2-85 Oral CDK8 inhibitor: Late Pre-Clinical, hematological malignancies
AU14-5 Oral CDK2 inhibitor: Late Pre-Clinical, hematological malignancies
AU4-53 Oral CDK9/TRK inhibitor: Late Pre-Clinical, All MCL1/MYC-dependent hematological cancer
AU5-5 Oral FLT3 inhibitor: Late Pre-Clinical, FL3-ITD+and-TKD mutant hematological malignancies
AU7-55 Oral TAM inhibitor: Late Pre-Clinical, hematological malignancies

Financial information

Investment sought: A$5M - A$20M

Project highlights

  • Australian, privately owned biotechnology company with 8 patented drug candidates in development.
  • Targeted therapies for a range of cancers including hematological malignancies, glioblastoma, colorectal cancer, prostate cancer, ovarian cancer and pancreatic cancer in late pre-clinical and early clinical trial stages.
  • Global market opportunity exceeding $30 billion and the opportunity to invest early in a rapidly growing Australian biotech.

Key organisations

  • Aucentra Therapeutics

Project timelines

Expected start date
December 01, 2020

Expected end date
December 01, 2023

Funding round finish date



View all investment opportunities